Back to Authors

Dodick, David W.

https://orcid.org/0000-0002-9486-6790

A5057290642 | I1330342723

Mayo Clinic

Atria Academy of Science and Medicine, New York, NY, United States

Citations 387

The King-Devick test (KDT) and visual contrast sensitivity test (VCS) in migraine: the effect of migraine attack on rapid eye movements and visual sensitivity (S43.004)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s43.004

Factors Associated with Acute Medication Overuse in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study (S43.002)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s43.002

Efficacy of Erenumab for the Treatment of Patients With Chronic Migraine With and Without Aura (S32.006)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.006

Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.005

Untangling the burden of menstrual migraine from headache day frequency: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study (S20.003)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s20.003

Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episo

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s20.001

Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.100

Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (P4.099)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.099

Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.093

Online Medical Education Improves Knowledge of Both Risk Factors for Chronification and Clinical Trial Data in Migraine (P3.147)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p3.147